Message Font: Serif | Sans-Serif
No. of Recommendations: 0

7:09AM IDEXX Labs beats by $0.04, reports revs in-line; raises low end FY13 EPS guidance, in-line; guides revs below consensus; guides FY14 EPS in-line, revs above consensus (IDXX) 105.97 : Reports Q3 (Sep) earnings of $0.86 per share, $0.04 better than the Capital IQ Consensus Estimate of $0.82; revenues rose 7.2% year/year to $338.3 mln vs the $339.91 mln consensus.

Commentary on Q
"...The third quarter saw the first full quarter of the sales transformation of our North American diagnostic sales professionals to a new, customer centric, sales role. In all, our sales professionals performed well against their diagnostic sales goals. While unit instrument placements were a little short of our expectation, the quality of placements was outstanding, supporting continued strong instrument consumable growth. We are encouraged that the one fifth of the regions that were in the new sales model for the second full quarter achieved instrument placements that were almost 20% higher than the prior year's third quarter. Further, we saw in the third quarter that more frequent sales representative visits resulted in both stronger loyalty and additional testing from our reference lab customers..."
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.